华大基因(300676) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 reached ¥1,563,364,152.52, representing a 97.60% increase compared to ¥791,193,880.94 in the same period last year[3] - Net profit attributable to shareholders was ¥524,980,701.18, a significant increase of 274.94% from ¥140,018,914.29 year-over-year[3] - The net profit after deducting non-recurring gains and losses was ¥540,667,084.22, up 369.01% from ¥115,278,149.38 in the previous year[3] - Basic earnings per share rose to ¥1.2909, reflecting a 268.83% increase compared to ¥0.3500 in the same quarter last year[3] - The company's operating revenue for Q1 2021 reached CNY 1,563.36 million, a year-on-year increase of 97.60%[12] - Net profit attributable to shareholders for the same period was CNY 524.98 million, representing a year-on-year growth of 274.94%[14] - The company reported a net profit of ¥3,545,458,260.77, up from ¥3,020,477,559.59, indicating a year-over-year increase of 17.4%[51] - Net profit for Q1 2021 was CNY 532,043,622.65, compared to CNY 136,518,623.16 in Q1 2020, representing a growth of 289.5%[57] Assets and Liabilities - Total assets at the end of the reporting period were ¥13,452,171,774.20, a 20.16% increase from ¥11,195,040,535.59 at the end of the previous year[3] - The total assets of the company as of March 31, 2021, were ¥13,452,171,774.20, compared to ¥11,195,040,535.59 at the end of 2020, marking a growth of 20.2%[51] - Total liabilities decreased to ¥4,882,533,182.51 from ¥5,169,299,593.44, a reduction of 5.6%[50] - The total liabilities decreased to CNY 1,452,948,309.75 from CNY 1,749,925,615.85, a reduction of 17.0%[54] - The company's total equity increased to CNY 7,549,006,941.96, up from CNY 5,482,336,678.81, reflecting a growth of 37.5%[54] Cash Flow - The net cash flow from operating activities decreased by 30.20% to ¥132,257,506.56 from ¥189,472,707.91 in the same period last year[3] - Cash flow from operating activities for Q1 2021 was ¥132,257,506.56, down from ¥189,472,707.91 in Q1 2020, indicating a decrease in cash generation[63] - The net cash flow from investment activities was -¥614,055,864.17, compared to -¥114,155,788.71 in the previous year, showing increased cash outflow for investments[63] - The net cash flow from financing activities was CNY 1,652,959,099.83, compared to CNY 646,467,736.21 in the previous period, indicating a significant increase[64] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 74,904, with the largest shareholder holding 35.94% of the shares[6] - The total number of unrestricted shares held by the top 10 shareholders is 38,827,000 shares, with the largest shareholder holding 38,827,000 shares[7] - The company has not conducted any repurchase transactions during the reporting period[8] - The company has a total of 3,469,498 restricted shares issued to Tianjin Liren Investment Management Partnership[9] - The company’s major shareholders include Shenzhen Huada Gene Technology Co., Ltd., holding 148,773,893 shares[9] Research and Development - The company completed technical testing for the V4.1 upgrade of its fully external product, enhancing functionality and performance[18] - Development and optimization of the sickle cell anemia gene testing product and reagent kit have been completed, expanding profit margins and supporting overseas expansion[18] - The company has completed the technical development and optimization design for the carrier screening product, enhancing market competitiveness[18] - The company is focusing on expanding its market presence and investing in new technologies to drive future growth[52] Market and Business Expansion - The company has signed a major contract with NUPCO worth up to USD 265.18 million for COVID-19 testing solutions, with cumulative recognized sales revenue of CNY 162.12 million[16][17] - The company aims to expand its global business and improve user engagement by enhancing its multi-omics data services and products[23] - The company has established subsidiaries in multiple countries, including Hong Kong, Europe, Japan, Singapore, and the United States, to support its global business expansion[27] Risk Management - The company is addressing operational risks due to the ongoing COVID-19 pandemic by optimizing its sales and R&D efforts to maintain market share[24] - The company is exposed to overseas business risks due to complex international political and economic environments, which may impact its operations[25] - The company has implemented measures to mitigate risks associated with being placed on the U.S. export control entity list, including maintaining communication with relevant authorities[25] Fundraising and Financial Management - The company raised a total of RMB 2,003,077,125 through the issuance of 13,814,325 shares, with a net amount of RMB 1,976,644,733.63 after deducting issuance costs[29] - The company has established special accounts for fundraising management to ensure the protection of investor rights[30] - The total amount of raised funds is RMB 247,289.47 million[38] - The total amount of raised funds used in the current quarter is RMB 56,565.08 million[38]